Synthetic Data - EabhaSeq Blog

EabhaSeq Back to main site

Synthetic Data

A collection of 3 posts

Why Rare Condition Screening is the Next Frontier in NIPT

Why Rare Condition Screening is the Next Frontier in NIPT

For most of its history, non-invasive prenatal testing has focused on a small set of common chromosomal conditions - trisomies 21, 18, and 13, along with sex chromosome aneuploidies. These conditions were the low-hanging fruit: they involve whole or large chromosomal changes that are relatively straightforward to detect from cell-free

The Reference Materials Problem in Prenatal Screening

The Reference Materials Problem in Prenatal Screening

In laboratory medicine, reference materials are the foundation of trust. They are well-characterized samples used to validate that a diagnostic test performs as expected - measuring the right thing, at the right sensitivity, with acceptable accuracy. Every clinical chemistry analyzer, every PCR-based infectious disease test, and every tumor marker assay

What is Synthetic cfDNA and Why Does it Matter for NIPT Validation?

What is Synthetic cfDNA and Why Does it Matter for NIPT Validation?

Non-invasive prenatal testing (NIPT) has transformed how we screen for chromosomal conditions during pregnancy. By analyzing fragments of cell-free DNA (cfDNA) circulating in a pregnant person's blood, clinicians can detect conditions like Down syndrome with remarkable accuracy - all from a simple blood draw. But behind every reliable